Welcome to our dedicated page for Relief Therapeut news (Ticker: RLFTY), a resource for investors and traders seeking the latest updates and insights on Relief Therapeut stock.
Relief Therapeutics (RLFTY) is a biopharmaceutical innovator developing patient-friendly therapies for rare metabolic, dermatological, and respiratory conditions. This page provides authorized updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.
Investors and healthcare professionals will find a comprehensive repository of verified news including trial results, partnership announcements, and financial reports. Key focus areas span proprietary formulation technologies, regulatory submissions, and commercialization efforts for treatments addressing critical unmet medical needs.
Content updates cover essential developments such as clinical study outcomes, FDA/EMA interactions, licensing agreements, and market expansion strategies. All materials are curated to support informed analysis of RLFTY’s progress in advancing therapies like its concentrated PKU formulations and stabilized antimicrobial solutions.
Bookmark this page for streamlined access to Relief Therapeutics’ latest advancements in rare disease research and development. Check regularly for objective updates on pipeline progress and corporate developments shaping the company’s trajectory.
Relief Therapeutics Holding SA announced key resolutions approved at its Extraordinary General Meeting on January 28, 2022, with over 85% support. Notably, Michelle Lock was elected to the Board of Directors, bringing extensive experience from Acceleron Pharma. The meeting also approved a total compensation of CHF 2,500,000 for board members for the current term and revised the Articles of Association. Relief's lead drug candidate, RLF-100, is in late-stage testing for COVID-19 respiratory issues, while partnerships expand its pipeline for rare diseases.
Relief Therapeutics Holding SA announced that its partner, NRx Pharmaceuticals, received a safety report on aviptadil use in COVID-19 patients under the Federal Right to Try Law. Out of 19 treated patients, three died while 16 (84%) were alive by January 22, 2022. The report noted no serious adverse events during the Omicron surge. Relief focuses on developing therapies for serious conditions, with aviptadil in late-stage testing for respiratory failure due to COVID-19, alongside other pipeline projects including ACER-001.
Relief Therapeutics announced that its subsidiary, APR Applied Pharma Research, received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent on diclofenac potassium formulations, extending protection until December 13, 2039. This patent covers ready-to-use oral solutions in stick packs for treating pain and migraine. The new formulation aims to enhance patient compliance. Current commercial rights for diclofenac are held by Assertio Therapeutics in the U.S. and Miravo Healthcare in Canada. The patent strengthens Relief's position in the market for non-steroidal anti-inflammatory drugs.
Relief Therapeutics Holding SA reported enhancements to the Expanded Access and Right to Try programs for aviptadil, enabling COVID-19 patients with respiratory failure to access treatment. These changes are made by their collaboration partner, NRx Pharmaceuticals. Patients who have exhausted all approved therapies can receive aviptadil via physician prescription, continuing under FDA guidelines. Relief's product, RLF-100 (aviptadil), is in late-stage trials for respiratory issues caused by COVID-19, while the company diversifies its pipeline through collaborations and acquisitions.
Relief Therapeutics commented on NRx Pharmaceuticals' press release regarding a lawsuit filed by NeuroRx against Relief. Relief asserts that the collaboration agreement for aviptadil remains valid and alleges that NeuroRx is in breach. The company refutes claims of financial impropriety and misleading statements made by NRx, asserting they are false and defamatory. Relief is poised to respond to NeuroRx's complaints and may file additional claims against them. The previously scheduled mediation date has been postponed due to NeuroRx's failure to provide required documentation.
Relief Therapeutics Holding SA announced that its collaboration partner, NeuroRx, has filed a lawsuit against it in New York, alleging breach of their collaboration agreement and defamation. Relief asserts that the agreement is still valid and disputes NeuroRx's claims. The company believes the lawsuit includes materially inaccurate statements and an illogical damages calculation. Relief plans to respond to the lawsuit and continues to participate in scheduled mediation with NeuroRx.
Relief Therapeutics announced that its partner, NRx Pharmaceuticals, submitted an application to the FDA for emergency use authorization (EUA) of aviptadil to treat COVID-19 patients at high risk of death. This application targets patients who are not eligible for the NIH-sponsored trial and are unresponsive to standard treatments like Remdesivir. Additionally, Relief is currently involved in a lawsuit against NeuroRx and its CEO, Jonathan Javitt, concerning their collaboration on aviptadil. The company remains optimistic about its legal claims and an upcoming mediation in February 2022.
Relief Therapeutics announced its participation in several virtual investor conferences in January 2022. The conferences include the H.C. Wainwright BioConnect Virtual Conference (January 10-13), where CFO Jack Weinstein will present an overview, and the Biotech Showcase 2022 (January 10-13, 17-19) for an additional corporate presentation. Relief's drug candidate, RLF-100, is in late-stage clinical testing for COVID-19 respiratory deficiency. The company is also expanding its pipeline through collaborations and acquisitions.
Relief Therapeutics has announced that its partner, NRx Pharmaceuticals, has filed a provisional patent application for stable compositions of aviptadil, a treatment for COVID-19. The application focuses on shelf-stable formulations of vasoactive intestinal peptide. Relief asserts that NRx has obligations under their collaboration agreement to cross-license related intellectual property to Relief, which plays a crucial role in an ongoing breach of contract lawsuit against NRx. Relief is also advancing its lead candidate RLF-100™ in late-stage clinical testing.
Relief Therapeutics Holding has announced an Extraordinary General Meeting (EGM) for shareholders on January 28, 2022, to be held virtually due to COVID-19 precautions. Key agenda items include:
- Election of Michelle Lock to the Board of Directors.
- Proposal for CHF 2,500,000 in compensation for Board members, up from CHF 1,500,000.
- General revision of Articles of Association, covering various amendments.
